Explore the latest sustainability reporting trends shaping the pharmaceutical industry and understand how leading organizations disclose, measure and manage their ESG performance.
Environmental, social and governance (ESG) reporting has become a strategic priority for pharmaceutical companies as climate, regulatory and stakeholder pressures intensify. Our latest ESG Research white paper analyzes disclosures from North America’s top 100 pharma companies, providing a clear view of reporting behaviors, material topics and emerging challenges. It equips you to strengthen your sustainability strategy and align with evolving global expectations.
In this comprehensive review, we examine how companies are responding to increasing regulatory demands, the rise of impact-driven investors and the growing market expectation for transparency and third-party assurance. These insights help you benchmark your progress, identify gaps and build a more resilient and credible ESG program.
